Open AccessSecondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study
Author(s) -
Oliver Zivanovic,
S. Dennis,
Qin Zhou,
Alexia Iasonos,
Jason Konner,
Vicky Makker,
Rachel N. Grisham,
Amy Brown,
Stacy Nerenstone,
John P. Diaz,
E. Schroeder,
Carrie Langstraat,
Viktoriya Paroder,
Yulia Lakhman,
Krysten Soldan,
Katy Su,
Ginger J. Gardner,
Vaagn Andikyan,
Jianxia Guo,
Elizabeth L. Jewell,
Kara Long Roche,
Tiffany A. Troso-Sandoval,
Stuart M. Lichtman,
Lea A. Moukarzel,
Kimberly Dessources,
Nadeem R. AbuRustum,
Carol Aghajanian,
William P. Tew,
Jan H. Beumer,
Yukio Sonoda,
Roisin E. O’Cearbhaill
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.00605
Subject(s) - medicine , carboplatin , hyperthermic intraperitoneal chemotherapy , surgery , chemotherapy , ovarian cancer , hazard ratio , perioperative , stage (stratigraphy) , cytoreductive surgery , gynecologic oncology , cancer , cisplatin , confidence interval , paleontology , biology
The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.